Overall, gene editing and pharmacological approaches have rendered promising findings on therapeutic strategies in preventing Ca2+ dysregulation, improving contractility and reducing arrhythmia susceptibility in order to alleviate these key pathological features of PLN-R14del pathophysiology. The gene discussed is PLN; the disease is cardiac arrhythmia.